🌱 Canada right now: Pacific 11:56 am Mountain 12:56 pm SK* 12:56 pm Central 1:56 pm Eastern 2:56 pm Atlantic 3:56 pm NL 4:26 pm *SK no DST
🏥 Canadian Health Policy · Sleep

Canadian guidelines for insomnia — what CADTH, Health Canada, and Canadian clinicians recommend

Canada has a distinct regulatory and clinical framework for insomnia treatment that differs meaningfully from US or UK guidelines. CADTH — Canada's independent health technology assessment body — has reviewed the evidence and consistently positions Cognitive Behavioural Therapy for Insomnia (CBT-I) as first-line treatment ahead of sleep medication. Health Canada separately regulates sleep aids including melatonin under its Natural Health Products framework. This page summarises what Canadian guidelines say, what is approved, and where to access evidence-based insomnia treatment in Canada.

✍️ GoToSleep.ca Editorial Team 📅 Updated April 26, 2026 ⏱ 8 min read

What Canadian guidelines say about insomnia

Insomnia is the most common sleep disorder in Canada, affecting an estimated 13% of Canadians with chronic symptoms (3+ nights per week for 3+ months) and a far larger proportion experiencing occasional or short-term insomnia. Note that seasonal affective disorder (SAD) causes a distinct sleep pattern — hypersomnia rather than insomnia — and has its own diagnostic and treatment pathway. Canadian clinical bodies — including the Canadian Sleep Society (CSS), the College of Family Physicians of Canada (CFPC), and CADTH — have each published guidance or evidence reviews that inform how Canadian clinicians should treat it.

The consistent message across all major Canadian guidelines is that Cognitive Behavioural Therapy for Insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia. Pharmacotherapy is positioned as a short-term adjunct or second-line option, not a primary treatment. This aligns with international guidelines from the American Academy of Sleep Medicine and European Sleep Research Society but applies specifically within Canada's healthcare and regulatory context.

CADTH insomnia review: CBT-I recommended as first-line treatment in Canada

CADTH insomnia evidence reviews recommend Cognitive Behavioural Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia in Canada. Pharmacotherapy is a short-term adjunct or second-line option only.

CADTH insomnia recommendation — full summary

CADTH evidence reviews find CBT-I produces durable benefits at 12–24 month follow-up; medication benefits cease on discontinuation. Digital CBT-I is considered clinically comparable to in-person therapy, improving access across rural and northern Canada.

CADTH (the Canadian Drug and Technologies in Health agency — now part of the broader Canadian health technology assessment framework) has published systematic reviews and rapid evidence reports on insomnia treatment. Key findings from CADTH insomnia reviews:

  • CBT-I produces durable outcomes: CADTH evidence reviews note that CBT-I benefits persist at 12- and 24-month follow-up, unlike pharmacotherapy whose effects are tied to continued use.
  • Pharmacotherapy is appropriate short-term: For acute insomnia (less than 4 weeks), short-term use of sleep medication may be appropriate as a bridge while CBT-I is initiated or accessed.
  • Z-drugs carry dependency risk: CADTH reviews highlight the dependency, tolerance, and rebound insomnia risks of z-drugs (zopiclone, zolpidem) and benzodiazepines, supporting guideline recommendations to limit their duration.
  • Digital CBT-I is effective: CADTH has reviewed digital health technologies and found app-based and internet-delivered CBT-I programs clinically comparable to therapist-delivered treatment, improving access in underserved regions of Canada.
What CADTH means for your treatment: If your family physician prescribes a sleeping pill as a first response to chronic insomnia without discussing CBT-I, that does not align with current Canadian evidence-based guidelines. You can ask specifically about CBT-I referral or access.

Health Canada approved treatments for insomnia

Health Canada regulates insomnia treatments across two streams: Natural Health Products (NHPs) and prescription or over-the-counter drugs.

Natural Health Products (NHPs)

Melatonin is the most significant NHP for insomnia in Canada. Unlike the US (where it is an unregulated supplement), Canadian melatonin products must carry an NPN (Natural Product Number) issued by Health Canada after pre-market review of safety, efficacy, and quality. Health Canada-approved melatonin indications include: sleep-onset insomnia, jet lag, and shift work sleep disorder. The approved dose range is 0.5–5 mg, with Health Canada guidance noting that lower doses (0.5–1 mg) are as effective as higher doses for most adults. Other NHP sleep aids — valerian, L-theanine, magnesium glycinate — may be sold with NPNs but with more limited efficacy claims.

Prescription sleep medications

Zopiclone (a z-drug) is the most commonly prescribed sleep medication in Canada and is only available by prescription. Benzodiazepines (temazepam, triazolam) are also prescribed but carry higher dependency risk. Health Canada has issued warnings on z-drugs regarding next-day impairment, particularly for driving, and recommends limiting use to the shortest effective duration.

OTC sleep aids

Diphenhydramine-based OTC sleep aids (Benadryl, ZzzQuil) are approved by Health Canada for occasional sleeplessness. Health Canada does not recommend these for chronic insomnia — tolerance develops within days, and antihistamine effects impair cognitive function the following day. They are not part of evidence-based insomnia treatment guidelines.

Canadian clinical practice guidelines

Several Canadian professional bodies have published or endorsed insomnia treatment guidelines:

  • Canadian Sleep Society (CSS): The CSS endorses CBT-I as first-line treatment and has advocated for better access to trained CBT-I providers across Canada. The CSS also recognises that the therapist shortage requires digital CBT-I as a practical alternative.
  • College of Family Physicians of Canada (CFPC): The CFPC's Choosing Wisely Canada campaign specifically recommends against prescribing sleep medication as first-line treatment for insomnia, and against routinely renewing sleep medication prescriptions without reassessment and discussion of CBT-I.
  • Canadian Psychiatric Association (CPA): CPA guidelines for insomnia comorbid with anxiety and depression recommend addressing the insomnia directly with CBT-I rather than assuming it will resolve when the mental health condition is treated.
  • Choosing Wisely Canada: This national initiative — endorsed by 40+ Canadian medical societies — includes specific recommendations against using benzodiazepines or z-drugs for insomnia in older adults, citing fall risk, cognitive impairment, and dependency.

Finding insomnia treatment in Canada

The largest practical barrier for Canadians is accessing CBT-I despite guidelines recommending it. Here are the routes available:

  • Ask your GP for a sleep clinic referral — sleep medicine clinics at major Canadian hospitals offer CBT-I; wait times vary by province
  • Extended health benefits — if your employer plan covers registered psychologists, CBT-I delivered by a psychologist trained in sleep qualifies
  • Digital CBT-I programs — Sleepio, Somryst (Health Canada cleared), and the free Insomnia Coach app deliver evidence-based CBT-I without waitlists
  • Provincial mental health programs — several provinces offer subsidised psychological therapy that can include CBT-I

For a full breakdown including city-by-city options, see our CBT-I treatment guide for Canadians →

Clinical practice guideline for insomnia in Ontario

Ontario has specific infrastructure for accessing insomnia treatment that differs from other provinces. For Ontarians seeking CBT-I or clinical insomnia care:

  • CAMH (Centre for Addiction and Mental Health): CAMH in Toronto offers sleep medicine assessment and CBT-I through its Mood and Anxiety Program. Referral through a family physician is typically required.
  • Ontario Sleep Clinics: Hospital-based sleep clinics at Sunnybrook, Toronto General, and Ottawa Hospital provide polysomnography and CBT-I programs. OHIP covers the assessment; CBT-I delivery varies by clinic.
  • ConnexOntario: Call 1-866-531-2600 to find provincially funded mental health programs, including those offering CBT for insomnia comorbid with anxiety or depression.
  • Employer extended health: Ontario's extended health plans frequently cover registered psychologist visits, which can include CBT-I. Confirm "insomnia" or "sleep disorders" is a covered presenting complaint with your insurer.
  • Ontario Drug Benefit (ODB): For insomnia medication, zopiclone is covered under ODB for eligible Ontarians. However, Ontario pharmacists are encouraged to initiate conversations about CBT-I as an alternative when presenting prescriptions for z-drugs — consistent with the Choosing Wisely Canada guidance endorsed by the Ontario College of Pharmacists.

There is no single Ontario-specific insomnia clinical practice guideline document separate from the national framework. Ontario clinicians follow CADTH evidence reviews, Canadian Sleep Society recommendations, and the College of Physicians and Surgeons of Ontario's prescribing guidance on benzodiazepines and z-drugs, which limits duration and requires periodic reassessment.

Frequently asked questions

Canadian guidelines — from CADTH, the Canadian Sleep Society, and the College of Family Physicians of Canada — identify CBT-I (Cognitive Behavioural Therapy for Insomnia) as the first-line treatment for chronic insomnia. Pharmacotherapy is a second-line or short-term adjunct. Health Canada regulates melatonin and sleep medications under its Natural Health Products and drug frameworks.

Ontario does not have a separate provincial insomnia guideline. Ontario clinicians follow CADTH evidence reviews, Canadian Sleep Society recommendations, and the CPSO's prescribing guidance on benzodiazepines and z-drugs. Ontarians can access CBT-I through CAMH, hospital sleep clinics (Sunnybrook, Toronto General, Ottawa Hospital), and employer-covered psychologist visits. ConnexOntario (1-866-531-2600) can direct to provincially funded options.

CADTH's evidence position on insomnia is that CBT-I is the recommended first-line treatment for chronic insomnia based on its durable outcomes (benefits persist at 12–24 months post-treatment), absence of side effects, and lack of dependency risk. Pharmacotherapy (z-drugs, benzodiazepines) is appropriate short-term but CADTH reviews highlight dependency and rebound risks. Digital CBT-I platforms are considered clinically comparable to therapist-delivered treatment.

Yes. CADTH evidence reviews consistently support CBT-I over pharmacotherapy for chronic insomnia based on durability of outcomes, absence of side effects, and lack of dependency risk. CADTH has also reviewed digital CBT-I platforms and found them clinically comparable to in-person therapy.

Health Canada approves melatonin as a Natural Health Product (with an NPN) at 0.5–5mg for sleep-onset insomnia, jet lag, and shift work. Zopiclone and benzodiazepines are prescription-only. OTC diphenhydramine products are approved for occasional sleeplessness only. CBT-I requires no Health Canada approval as it is a therapy, not a product.

Canadian guidelines for chronic insomnia — defined as 3+ nights per week for 3+ months — position CBT-I as first-line treatment. This is consistent across CADTH evidence reviews, the Canadian Sleep Society, and Choosing Wisely Canada recommendations. Pharmacotherapy is not recommended as a first-line or long-term treatment for chronic insomnia due to dependency and rebound risks.

Canadian insomnia treatment guidelines recommend CBT-I as first-line for chronic insomnia. Short-term sleep medication may be appropriate for acute or situational insomnia. Health Canada regulates melatonin as a Natural Health Product (NPN required) at 0.5–5 mg for sleep onset, jet lag, and shift work. OTC antihistamine sleep aids are not part of evidence-based guidelines.